Oncology News

In a cohort of Chinese patients, researchers found that routine blood and urine test results may be useful for predicting the probabilities of the risk for hepatocellular carcinoma, according to a poster presentation at the European Society for Medical Oncology’s European Cancer Congress.

Isolated hepatic perfusion was an effective treatment for patients with uveal melanoma who developed unresectable metastases confined to the liver, according to a poster presentation at the European Society for Medical Oncology’s European Cancer Congress.

Routine ultrasonographic surveillance led to improved survival and reduced mortality risk in patients with viral hepatitis and hepatocellular carcinoma, according to published findings.

Colorectal and hepatic resections for stage 4 metastatic colorectal cancer influenced postoperative outcomes, with minor hepatectomy associated with lower rates of mortality and major morbidity and major hepatectomies associated with higher rates of both, according to published findings.

The FDA has granted fast track designation to Can-Fite BioPharma Ltd.’s CF102, a potential drug to treat hepatocellular carcinoma, according to a press release.

Researchers from the Veterans Affairs Puget Sound Health Care System, Seattle, Washington, found that the hepatocellular carcinoma MELD exception policy reduces liver transplantation-related survival benefit in patients with hepatocellular carcinoma, according to published findings.

Researchers found that the use of positron emission tomography with [18F]FDG in combination with magnetic resonance imaging was more accurate in detecting liver metastases compared with positron emission tomography with computed tomography, according to published findings.

Researchers at Hiroshima University found circulating tumor DNA to be an accurate predictor of hepatocellular carcinoma recurrence within 2 years of liver resection, according to newly published data.

In a prospective study, researchers in Italy found that compensated patients with hepatocellular carcinoma who permanently discontinued therapy with Nexavar had a longer post-treatment survival, according to published findings in Hepatology.

The National Cancer Institute awarded Wei Jia, MD, shared resources director at the University of Hawaii Cancer Center, a $2.7 million grant for his liver cancer prevention study, according to a press release from the University of Hawaii Cancer Center.